Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Physiologically based pharmacokinetic/toxicokinetic modeling.

Campbell JL Jr, Clewell RA, Gentry PR, Andersen ME, Clewell HJ 3rd.

Methods Mol Biol. 2012;929:439-99.

PMID:
23007440
2.

Toxicokinetic modeling and its applications in chemical risk assessment.

Andersen ME.

Toxicol Lett. 2003 Feb 18;138(1-2):9-27. Review.

PMID:
12559690
3.

Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.

Clewell HJ 3rd, Gentry PR, Gearhart JM.

J Toxicol Environ Health. 1997 Dec 26;52(6):475-515.

PMID:
9397182
4.

PBPK models in risk assessment--A focus on chloroprene.

DeWoskin RS.

Chem Biol Interact. 2007 Mar 20;166(1-3):352-9.

PMID:
17324392
5.

Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.

Krishnan K, Johanson G.

J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005;23(1):31-53. Review.

PMID:
16291521
7.

Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.

Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H.

J Pharmacokinet Biopharm. 1995 Apr;23(2):217-29. Review.

PMID:
8719238
8.

Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.

Kedderis GL, Lipscomb JC.

Toxicol Ind Health. 2001 Jun;17(5-10):315-21.

PMID:
12539878
9.

Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans.

Sarangapani R, Teeguarden JG, Cruzan G, Clewell HJ, Andersen ME.

Inhal Toxicol. 2002 Aug;14(8):789-834.

PMID:
12122565
10.

The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures.

Yang RS, el-Masri HA, Thomas RS, Constan AA.

Toxicol Lett. 1995 Dec;82-83:497-504. Review.

PMID:
8597101
11.

Have physiologically-based pharmacokinetic models delivered?

Edginton AN, Joshi G.

Expert Opin Drug Metab Toxicol. 2011 Aug;7(8):929-34. doi: 10.1517/17425255.2011.585968.

PMID:
21762039
12.

Physiologically based pharmacokinetics (PBPK).

EspiƩ P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB.

Drug Metab Rev. 2009;41(3):391-407. doi: 10.1080/10837450902891360. Review.

PMID:
19601719
13.

Application of physiologically based pharmacokinetic modelling to combination toxicology.

Simmons JE.

Food Chem Toxicol. 1996 Nov-Dec;34(11-12):1067-73. Review.

PMID:
9119317
14.

Physiologically based pharmacokinetic analyses of simple mixtures.

Krishnan K, Clewell HJ 3rd, Andersen ME.

Environ Health Perspect. 1994 Nov;102 Suppl 9:151-5. Review.

15.

A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment.

Clewell HJ 3rd, Andersen ME, Barton HA.

Environ Health Perspect. 2002 Jan;110(1):85-93.

16.

The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures.

Yang RS, el-Masri HA, Thomas RS, Constan AA, Tessari JD.

Toxicol Lett. 1995 Sep;79(1-3):193-200. Review.

PMID:
7570656
17.
19.
20.

Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.

Xia B, Heimbach T, Lin TH, He H, Wang Y, Tan E.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1567-82. doi: 10.1007/s00280-012-1863-5.

PMID:
22526410
Items per page

Supplemental Content

Support Center